Why is Eli Lilly acquiring AtaiBeckley?

To expand its neuroscience pipeline, particularly in treatment-resistant depression and anxiety disorders.

What regulatory challenges are expected for the deal?

Antitrust review in the U.S. and Europe is expected, potentially requiring divestitures.

Eli Lilly to Acquire AtaiBeckley for Up to $3.8B to Boost Neuroscience Pipeline

Q: How did AtaiBeckley's stock react to the acquisition news?

ATAI shares surged over 30% on Thursday.

Eli Lilly (LLY) announced an agreement to acquire AtaiBeckley (ATAI) for up to $3.8 billion, aiming to expand its neuroscience pipeline. ATAI shares surged over 30% on Thursday following the announcement.

July 16, 2026

2 min read

Source: MT Newswires

Key Numbers

deal value

3.8B

target ticker

ATAI

acquirer ticker

LLY

Eli Lilly (NYSE: LLY) announced an agreement to acquire AtaiBeckley (NASDAQ: ATAI) for up to $3.8 billion, in a deal aimed at strengthening the company's presence in neuroscience. ATAI shares surged over 30% in Thursday trading following the announcement.

Deal Details

Total Value: Up to $3.8 billion.
Payment Method: Not yet disclosed (cash or stock).
Premium: Not specified.
Expected Close: Subject to regulatory approvals and customary closing conditions.

Rationale for the Deal

Eli Lilly seeks to expand its neuroscience pipeline, a strategic area for the company. AtaiBeckley has promising drug candidates in late-stage development, particularly for treatment-resistant depression and anxiety disorders.

Regulatory Challenges

The deal is expected to face antitrust review in the U.S. and Europe. Given its size, regulators may require divestitures or impose conditions.

Impact on Stocks

LLY: The stock may see slight short-term pressure due to acquisition costs, but investors view the deal as positive for long-term growth.
ATAI: The stock jumped over 30%, reflecting market optimism about the deal's completion and expected premium.

Frequently Asked Questions

The deal is valued at up to $3.8 billion.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.